# Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)

> **NCT04633226** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 58 (actual)

## Conditions studied

- Pneumococcal Disease

## Interventions

- **BIOLOGICAL:** V114

## Key facts

- **NCT ID:** NCT04633226
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-10
- **Primary completion:** 2022-11-04
- **Final completion:** 2022-11-04
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04633226

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04633226, "Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04633226. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*